Technicals Stability Returns

Fundamental Analysis of Natco Pharma (NATCOPHARM)

Summary    Balance Sheet    Cash Flow    Income    Qtrly Income    Valuation Ratio    Profitability Ratios    Solvency    Efficiency Ratios    

Guru Numbers
Book Value/Share233.60
EV/EBITDA37.86
Market Cap (Cr)9659.09
Enterprise Value (Cr)9580.59
Piotroski F-Score5.00
Altman Z Score8.54
Graham No342.50
Price/ Graham 1.54
Peter Lynch Ratio-2.59
Sloan Ratio0.0252
Peter Lynch Fair valueNA
TSR Fair value663.21
Key Financial ratios of NATCOPHARM
Ratio Latest FY Yoy Change TTM MRQ Screener/
About
Price to Earning    81.18 137.78 % 23.71    
Price to Book    3.24 -11.37 % 2.18 2.11    
Price to Sales    7.10 -3.34 % 3.90    
Earning Per Share    9.31 -61.48 % 22.32 3.11    
Return On Equity    3.99 -62.73 % 9.44 1.24    
Return On Asset    3.33 -63.84 % 8.01 1.12    
Net Profit Margin    8.74 -59.32 % 16.46 13.15    
Operating Profit Margin    5.31 -77.12 % 16.91 12.40    
EBITDA Margin    18.64 -46.11 % 27.19 26.80    
Debt to Equity Ratio    0.0039 -94.38 % 0.0185    
Current Ratio    3.52 -20.95 % 6.00    
Quick Ratio    2.30 -21.39 % 4.13    
View Historitcal ratios of Natco Pharma Ltd.
Valuation Ratios   Profitability Ratio   Solvency Ratios   Efficiency Ratios
Screen Financial Ratio using Custom Screener
Terrific View
Tsr Stability Index - Excellent Score of 93.75
Altman Z Score of 8.51 suggests good Stability
Undervalued - Price to Intrinsic Value of 0.794
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
All key Trailing Twelve Months Margin growing by 15 %
Steady View
Piotroski F Score - Stable Value of 5.0
Steady increase in Total Assets for last 3 Years
Book Value in last 3 years is trending up
Good Net Margin of 16.46% is achieved by the company
Risky View
Tsr Value Index - Very Poor Score of 18.06
Tsr Growth Index - Very Poor Score of 14.13
Tsr Profitability Index - Poor Score of 21.88
Stock Returns < -43.89 % Than Nifty in last one year
Stock Returns is less than Nifty returns for consequitive last three years
Operating Cash Flow decreasing for last 3 year
Company is unable to generate enough free cash to support the business.
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned48.80 %
Institution Owned26.00 %
Public/Others25.20 %
Outstanding Shares18.26 Cr
Floating Shares8.43 Cr
Floating / Outstanding46.20%
Book Value/Share233.60
Face value2.00
Share Holding
Annual Key Income Statement of NATCOPHARM
Period 31_Mar_2022 31_Mar_2021 Growth
Net Income From Continuing Ops 170.00 442.40 61.57 %
Net Income 170.00 440.90 61.44 %
Operating Income 103.20 476.00 78.32 %
Total Revenue 1944.80 2052.10 5.23 %
Operating Expense 1841.60 1576.10 16.85 %
Interest Expense 17.70 13.30 33.08 %
Tax Expense 32.20 137.20 76.53 %
Income Before tax 202.20 579.60 65.11 %
Gross Profit 1383.90 1082.40 27.85 %
Dividend Paid -82.20 -113.90 27.83 %
   
Quarterly Key Income Statement of NATCOPHARM
Period 30_Sep_2022 30_Jun_2022 Growth
Net Income From Continuing Ops 56.80 320.40 82.27 %
Net Income 56.80 320.40 82.27 %
Operating Income 53.60 355.70 84.93 %
Total Revenue 432.10 884.60 51.15 %
Operating Expense 336.80 528.90 36.32 %
Interest Expense 3.80 4.20 9.52 %
Tax Expense 13.50 65.40 79.36 %
Income Before tax 70.30 385.80 81.78 %
Gross Profit 326.30 736.90 55.72 %
Dividend Paid -63.90 0 %
   
Key Balance Sheet Fields
Period 31_Mar_2022 31-Mar-21 Growth
Common Stock 36.50 36.50 0 %
Current Liabilities 710.40 525.60 35.16 %
Total Liabilities 845.50 670.30 26.14 %
Current Assets 2497.20 2337.30 6.84 %
Total Assets 5109.10 4791.90 6.62 %
Working capital 1786.80 1811.70 1.37 %
Accounts Payable 161.80 146.20 10.67 %
Inventory 862.00 798.20 7.99 %
Net Receivable 620.60 412.90 50.30 %
   
Key Cash Flow Fields
Period 31_Mar_2022 31_Mar_2021 Growth
Cash EPS 17.13 30.65 44.11 %
Cash From Investment Activity -5.30 -103.30 94.87 %
Cash From Financial Activity 34.80 -185.70 118.74 %
Cash Operational Activity 46.50 298.80 84.44 %
Net Cash Flow 76.00 9.80 675.51 %
NetIncome 170.00 440.90 61.44 %
Capital Expenditure 232.80 254.60 8.56 %
Change To Inventory 56.40 -240.20 123.48 %
   



   About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF; and agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. The company markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Address : NATCO House, Hyderabad, India, 500034

URL : https://www.natcopharma.co.in

Employee Count : 4025

About TSR TECH Strength / Valuation / Growth

TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick

TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential

TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value

This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback

We are working on fundamental strength also. Please share your views to help shape up the requirement.